Biocon signs agreement with Biomm for generic Semaglutide commercialisation in Brazil

19 April 2024 | News

Semaglutide (gOzempic) is used to improve glycemic control in adults with type-2 diabetes

image credit- shutterstock

image credit- shutterstock

Bengaluru-based biopharmaceutical firm Biocon has announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.

Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market.

Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments. The company focuses on developing, manufacturing and commercializing complex biotech and biosimilar drug products at their state-of-the-art production facility in Nova Lima.

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, said, “Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides. This is also in line with our growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products.”

Heraldo Marchezini, Chief Executive Officer, Biomm, commented: “Brazil is the fifth country in the world with the highest incidence of diabetes, having 16.8 million adults in the age group of 20 to 79 years with the disease, and an estimated 21.5 million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF)."

The total addressable market opportunity of Semaglutide in Brazil is approximately $580 million as per the IQVIA MAT Q4 2023


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account